Well-balanced & Patient-centric Innovation
As of August 2024
Classifications
Indication
Product Candidate
Discovery
Preclinical
Phase 1
Phase 2
Biologics
Drug
Dispersion Agent
HLB3-002
(rHuPH20 stand-alone)
Biologics
Alzheimer's
Disease
HLB1-014
(anti-Aβ mAb)
HLB1-014 (Anti-Aβ mAb for Alzheimer’s Disease, Best in class)
HLB1-014 (Anti-Aβ mAb, Best-in-Class) is a preclinical-stage therapeutic candidate developed to treat Alzheimer’s disease by targeting amyloid-beta (Aβ) plaques. This monoclonal antibody (mAb) binds specifically to Aβ plaques, promoting their clearance from the brain. By reducing existing plaques and preventing the formation of new ones, HLB1-014 aims to mitigate the symptoms and slow the progression of Alzheimer’s disease with high specificity and minimal off-target effects.
Biologics
Osteoporosis
HLB3-013
(Denosumab biosimilar)
HLB3-013 (Denosumab biosimilar)
HLB3-013 (denosumab biosimilar) is a preclinical-stage biosimilar candidate that has demonstrated equivalent quality and efficacy to the reference product, Prolia®, in preclinical studies.
Denosumab, developed by Amgen and marketed under the brand names Prolia® and Xgeva®, functions by inhibiting RANKL, thereby reducing bone resorption and increasing bone mass. Prolia® is indicated for the treatment of osteoporosis, with 2023 sales reaching $4 billion. Xgeva® is indicated for preventing skeletal-related events in patients with bone metastases, treating giant cell tumor of bone, and managing hypercalcemia of malignancy, achieving $2.1 billion in sales in 2023 (Amgen)
Peptides
Obesity
HLB1-015
(Long-acting GLP-1R/-2R dual agonist)
HLB1-015 (Long-acting GLP-1R/-2R dual agonist)
HLB1-015 is a preclinical-stage therapeutic candidate designed to treat obesity by leveraging the benefits of long-acting GLP-1 (glucagon-like peptide-1) and GLP-2 (glucagon-like peptide-2). These dual agonist aims to enhance weight loss by reducing appetite, slowing gastric emptying, and promoting a feeling of fullness. By mimicking the body's natural incretin hormones, HLB1-015 can potentially provide sustained weight management with minimal side effects, offering a promising solution for individuals struggling with obesity.
Peptides
Obesity
HLB1-016
(Long-acting GIPR antagonist)
HLB1-016 (Long-acting GIPR antagonist)
HLB1-016 is a discovery-stage therapeutic candidate focused on treating obesity by utilizing a long-acting GIPR (gastric inhibitory polypeptide receptor) antagonist in combination with a GLP-1R/-2R agonist. This approach inhibits the GIP receptor to reduce energy storage and fat accumulation while also activating the GLP receptors to enhance metabolic benefits and weight loss. By blocking GIPR and activating GLP-R, HLB1-016 aims to reduce food intake, enhance fat utilization, and improve insulin sensitivity, offering a novel and promising approach to obesity management with the potential for high efficacy and minimal adverse effects.
Peptides
Short Bowel
Syndrome
HLB1-006
(Long-acting GLP-1R/-2R dual agonist)
HLB1-006 (Long-acting GLP-1R/-2R dual agonist)
HLB1-006 is a preclinical-stage therapeutic candidate intended for the treatment of short bowel syndrome (SBS) through the combined action of long-acting GLP-1R (glucagon-like peptide-1 receptor) and GLP-2R (glucagon-like peptide-2 receptor) dual agonists. This dual agonist aims to improve intestinal adaptation, enhance nutrient absorption, and reduce the need for parenteral nutrition in patients with SBS. By leveraging the synergistic effects of GLP-1R and GLP-2R activation, HLB1-006 has the potential to significantly improve the quality of life for individuals suffering from this challenging condition.